Lupus Erythematosus, Systemic Clinical Trial
Official title:
Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)
Systemic Lupus Erythematosus (SLE) is chronic and systemic autoimmune disease that mainly
affecting women and leading to organ damages especially skin, joints, kidneys, central
nervous system and heart. In SLE, immune system dysfunction leads to autoantibodies,
autoreactive T cells and pro-inflammatory cytokines production. These elements will initiate
and maintain organ damages. Patients with SLE have disease flares followed by period of
remission. Flares can occur because of stress, infections, surgery, pregnancy or ultraviolet
exposition. Furthermore the chronic nature of SLE is an important factor of depression in
these patients.
Qi Gong is an ancient Chinese practice based on relaxation movements, posture and breathing
in order to harmonize the body and mind. This practice improves the general state by reducing
fatigue and improving sleep. The beneficial effect of Qi Gong in medicine has been studied in
several diseases including cancer, diabetes, arterial hypertension and fibromyalgia. Qi Gong
seems interesting in depressed patients but also to reduce stress in healthy subjects.
The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients
with SLE. Patients will have two lessons of 60 minutes per week for three months and a
collective lesson of 90 minutes per week for three months. The teacher of Qi-Gong will
evaluate adherence to the practice of Qi Gong every week. Clinical and biological data will
be collected at baseline and at 2th, 4th, 6th, 9th and 12th month. Different evaluation
scores and neurotrophin levels will be collected at baseline and at 6th month.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
| Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
| Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
| Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
| Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
| Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
| Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
| Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|